Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
54
Views
0
CrossRef citations to date
0
Altmetric
Review

Clinical Application of Tumor Vascular Disrupting Therapy: A Systematic Review and Meta-Analysis

Wen Tsang1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1820-1017View further author information
ORCID Icon,
Lu Gan1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of ChinaView further author information
,
Zhikun Zhang1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of China;3 Mental Health Center, the Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of ChinaView further author information
,
Tong Li1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of ChinaView further author information
,
Yiqun Luo1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of ChinaView further author information
,
Liping Zhong1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Yong Huang1 National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;2 Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning,, Guangxi, 530021, People's Republic of ChinaView further author information
 show all
Pages 5085-5093 | Published online: 20 Oct 2021

Figures & data

Figure 1 PRISMA flow diagram of included studies.

Notes: PRISMA figure adapted from Moher D, Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of clinical epidemiology. 2009;62(10). Creative Commons.Citation14
Figure 1 PRISMA flow diagram of included studies.

Table 1 Basic Characteristics of the 8 Trials Included in the Meta-Analysis

Figure 2 Risk of bias graph (A) and risk of bias summary (B) for all included trials.

Figure 2 Risk of bias graph (A) and risk of bias summary (B) for all included trials.

Figure 3 Forest plot diagram of the objective response rate. (A) Forest plot diagram analysed using random-effects model. (B) Forest plot diagram analysed using fixed-effects model.

Figure 3 Forest plot diagram of the objective response rate. (A) Forest plot diagram analysed using random-effects model. (B) Forest plot diagram analysed using fixed-effects model.

Figure 4 Forest plot diagram of the disease control rate.

Figure 4 Forest plot diagram of the disease control rate.

Figure 5 Forest plot diagram of the 6-month progression-free survival rate.

Figure 5 Forest plot diagram of the 6-month progression-free survival rate.

Figure 6 Forest plot diagram of the 12-month progression-free survival rate.

Figure 6 Forest plot diagram of the 12-month progression-free survival rate.

Figure 7 Forest plot diagram of the 0.5‑year survival rate.(A) Forest plot diagram analysed using random-effects model. (B) Forest plot diagram analysed using fixed-effects model.

Figure 7 Forest plot diagram of the 0.5‑year survival rate.(A) Forest plot diagram analysed using random-effects model. (B) Forest plot diagram analysed using fixed-effects model.

Figure 8 Forest plot diagram of the 1‑year survival rate.

Figure 8 Forest plot diagram of the 1‑year survival rate.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.